Literature DB >> 31995405

ACKR2 contributes to pulmonary dysfunction by shaping CCL5:CCR5-dependent recruitment of lymphocytes during influenza A infection in mice.

Luciana P Tavares1,2, Cristiana C Garcia3, Ana Paula F Gonçalves2,4, Lucas R Kraemer1, Eliza M Melo2, Fabrício M S Oliveira1,5, Camila S Freitas1, Gabriel A O Lopes1, Diego C Reis1,5, Geovanni D Cassali5, Alexandre M Machado4, Alberto Mantovani6,7, Massimo Locati6,8, Mauro M Teixeira2, Remo C Russo1,2.   

Abstract

Inflammation triggered by influenza A virus (IAV) infection is important for viral clearance, induction of adaptive responses, and return to lung homeostasis. However, an exaggerated immune response, characterized by the overproduction of chemokines, can lead to intense lung injury, contributing to mortality. Chemokine scavenger receptors, such as ACKR2, control the levels of CC chemokines influencing the immune responses. Among the chemokine targets of ACKR2, CCL5 is important to recruit and activate lymphocytes. We investigated the role of ACKR2 during IAV infection in mice. Pulmonary ACKR2 expression was increased acutely after IAV infection preceding the virus-induced lung dysfunction. ACKR2-knockout (ACKR2-/-) mice were protected from IAV, presenting decreased viral burden and lung dysfunction. Mechanistically, the absence of ACKR2 resulted in augmented airway CCL5 levels, secreted by mononuclear and plasma cells in the lung parenchyma. The higher chemokine gradient led to an augmented recruitment of T and B lymphocytes, formation of inducible bronchus-associated lymphoid tissue and production of IgA in the airways of ACKR2-/- mice post-IAV. CCL5 neutralization in ACKR2-/- mice prevented lymphocyte recruitment and increased bronchoalveolar lavage fluid protein levels and pulmonary dysfunction. Finally, CCR5-/- mice presented increased disease severity during IAV infection, displaying increased neutrophils, pulmonary injury and dysfunction, and accentuated lethality. Collectively, our data showed that ACKR2 dampens CCL5 levels and the consequent recruitment of CCR5+ T helper 1 (Th1), T regulatory cells (Tregs), and B lymphocytes during IAV infection, decreasing pathogen control and promoting lung dysfunction in wild type mice. Therefore, ACKR2 is detrimental and CCR5 is protective during IAV infection coordinating innate and adaptive immune responses in mice.

Entities:  

Keywords:  ACKR2; CCL5; IgA; iBALT; influenza A infection

Year:  2020        PMID: 31995405     DOI: 10.1152/ajplung.00134.2019

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

Review 1.  The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

Authors:  Arezoo Gowhari Shabgah; Farhad Jadidi-Niaragh; Hamed Mohammadi; Farnoosh Ebrahimzadeh; Maziar Oveisee; Abbas Jahanara; Jamshid Gholizadeh Navashenaq
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  Circulating Nestin-GFP+ Cells Participate in the Pathogenesis of Paracoccidioides brasiliensis in the Lungs.

Authors:  Leda M C Coimbra-Campos; Walison N Silva; Ludmila M Baltazar; Pedro A C Costa; Pedro H D M Prazeres; Caroline C Picoli; Alinne C Costa; Beatriz G S Rocha; Gabryella S P Santos; Fabrício M S Oliveira; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Danielle G Souza; Remo C Russo; Rodrigo R Resende; Akiva Mintz; Alexander Birbrair
Journal:  Stem Cell Rev Rep       Date:  2021-05-18       Impact factor: 5.739

Review 3.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

4.  CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.

Authors:  Xiao L Chang; Helen L Wu; Gabriela M Webb; Meenakshi Tiwary; Colette Hughes; Jason S Reed; Joseph Hwang; Courtney Waytashek; Carla Boyle; Cleiton Pessoa; Andrew W Sylwester; David Morrow; Karina Belica; Miranda Fischer; Scott Kelly; Nader Pourhassan; Rachele M Bochart; Jeremy Smedley; Christopher P Recknor; Scott G Hansen; Jonah B Sacha
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 8.786

Review 5.  The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities.

Authors:  Maximiliano Ruben Ferrero; Luciana Pádua Tavares; Cristiana Couto Garcia
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

6.  Comprehensive Genetic Analysis of Tuberculosis and Identification of Candidate Biomarkers.

Authors:  Zilu Wen; Liwei Wu; Lin Wang; Qinfang Ou; Hui Ma; Qihang Wu; Shulin Zhang; Yanzheng Song
Journal:  Front Genet       Date:  2022-03-07       Impact factor: 4.599

7.  Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.

Authors:  Yingqing Deng; Yuan Tan; Dongmei Zhou; Youhuang Bai; Ting Cao; Caizhou Zhong; Weilai Huang; Yuhua Ou; Linlang Guo; Qianqian Liu; Deling Yin; Lipai Chen; Xiping Luo; Deqiang Sun; Xiujie Sheng
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 8.  Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19.

Authors:  Ronen Alon; Mike Sportiello; Stav Kozlovski; Ashwin Kumar; Emma C Reilly; Alexander Zarbock; Natalio Garbi; David J Topham
Journal:  Nat Rev Immunol       Date:  2020-11-19       Impact factor: 53.106

9.  CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice.

Authors:  Maximiliano Ruben Ferrero; Cristiana Couto Garcia; Marcella Dutra de Almeida; Jullian Torres Braz da Silva; Daniella Bianchi Reis Insuela; Tatiana Paula Teixeira Ferreira; Diego de Sá Coutinho; Carolina Trindade de Azevedo; Patrícia Machado Rodrigues E Silva; Marco Aurélio Martins
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.